An Epidemiology Model for Estimating the Numbers of US Patients With Multiple Myeloma by Line of Therapy and Treatment Exposure
- 11 August 2022
- journal article
- research article
- Published by Elsevier BV in Value in Health
- Vol. 25 (12), 1977-1985
- https://doi.org/10.1016/j.jval.2022.05.011
Abstract
No abstract availableKeywords
Funding Information
- GlaxoSmithKline
This publication has 28 references indexed in Scilit:
- Multiple myeloma: patient outcomes in real‐world practiceBritish Journal of Haematology, 2016
- Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practicesExpert Review of Hematology, 2016
- Patient population with multiple myeloma and transitions across different lines of therapy in the USA: an epidemiologic modelPharmacoepidemiology and Drug Safety, 2016
- Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myelomaBlood, 2014
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patientsLeukemia, 2013
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group studyLeukemia, 2011
- Solving Differential Equations inR: PackagedeSolveJournal of Statistical Software, 2010
- Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple MyelomaThe New England Journal of Medicine, 2007
- Rates and Probabilities in Economic ModellingPharmacoEconomics, 2007
- Clinical Course of Patients With Relapsed Multiple MyelomaMayo Clinic Proceedings, 2004